[4] Users should discontinue use if they experience any signs of allergic reactions, such as redness, hives, or itchiness
[1] After review, the FDA concluded that there is no clinical need to add semaglutide, tirzepatide, or liraglutide to the bulks list
Injection site reactions are the most frequently reported form of hypersensitivity with injectable GLP-1 agonists
COA from the manufacturer, not a third party
doi: 10.1016/j.ciresp.2023.01.012 11 ClavienPABarkunJDe OliveiraMLVautheyJNDindoDSchulickRDet al
Last reviewed: June 5, 2026 Last updated: June 5, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations